AbbVie Hit Harder By EU Humira Biosimilars Than Projected
Executive Summary
The Q3 earnings call was the first time AbbVie management had to face the masses since the mid-October launch of adalimumab biosimilars across Europe. CEO Gonzalez predicted ex-US Humira revenue erosion of 26%-27% this year, higher than previous estimates.
You may also be interested in...
AbbVie Defends Humira With Aggressive Discount In First EU Tender
AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.
Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?
Sandoz has become the latest firm to sign a settlement agreement over biosimilar Humira with AbbVie, heralding imminent launch in Europe. In the US, it will hold off launching until September 2023.
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
By marketing its own authorized generic versions of blockbuster HCV combos Epclusa and Harvoni, Gilead may eat into AbbVie’s large market share edge in US government-insured patients.